Latisse effective for treating eyebrow hypotrichosis
Latisse, applied once or twice daily for 7 months, was effective and safe compared with vehicle in treating eyebrow hypotrichosis, according to study results.
Jean Carruthers, MD, and colleagues conducted a multicenter, double-masked study of 357 adults (94.7% women; mean age, 54 years) with eyebrow hyperhidrosis, defined as either a grade 1 or 2 (very sparse or sparse) on the Allergan Global Eyebrow Assessment (GEBA) scale. The patients were randomized to receive Latisse (bimatoprost 0.03%, Allergan plc) twice daily (n=118) or once daily (n=118) or vehicle twice daily (n=121) for 7 months. Overall eyebrow fullness at 7 months was the primary endpoint.
Latisse was approved by the FDA in 2008 for treating hypotrichosis of the eyelashes.
There were 339 adults who completed the study. There were 83.9% of patients in the bimatoprost twice-daily group and 77.1% in the once-daily group with at least a 1-grade improvement in the GEBA scale from baseline at month 7, compared with 43% in the vehicle cohort (P < .001, both comparisons). Both bimatoprost treatment cohorts displayed significant improvements compared with the vehicle cohort after 1 month, which continued during the treatment and post-treatment periods (P ≤ .035, all comparisons).
Both bimatoprost treatment groups had improvement in eyebrow fullness and darkness by month 2 compared with the patients in the vehicle cohort (P ≤ 001, both).
There were 17.8% of patients in the bimatoprost twice-daily cohort, 16.9% in the bimatoprost once-daily cohort and 11.6% in the vehicle cohort who reported being “very satisfied” with their eyebrow look at month 7. Both bimatoprost treatment cohorts reported a significantly greater proportion of patients who reported ‘very satisfied or mostly satisfied” compared with the patients in the vehicle cohort (P ≤ .031).
“Overall, 38.1%, 42.4% and 35.5% of subjects in the bimatoprost [twice-daily], [once-daily] and vehicle groups, respectively, experienced ≥ 1 treatment-emergent adverse event,” the researchers reported.
There were no reports of skin or iris hyperpigmentation or conjunctival hyperemia.
“Bimatoprost 0.03% is a safe, well-tolerated and effective treatment for hypotrichosis of the eyebrows in this population,” the researchers concluded. “Improvements in eyebrow growth and subject satisfaction appeared within 1 to 2 months and were sustained through the study period. The safety profile of bimatoprost … is in line with that shown in previous large, controlled studies of bimatoprost for treatment of eyelash hypotrichosis.” – by Bruce Thiel
Disclosure: The study was supported by Allergan, plc, with writing and editorial support provided by Peloton Advantage. Carruthers reports serving as a consultant for and receiving research grants from Allergan plc. Please see the full study for a list of other researchers’ relevant financial disclosures.